GEO series
Imaging-based drug screening combined with moleuclar profiling identifies signatures and drivers of therapy resistance in pediatric AML [ATAC-seq]
GSE282258
Homo sapiens
Genome binding/occupancy profiling by high throughput sequencing
44 samples
Submitted 2025/05/02
Platform GPL24676
Summary
Despite recent advances in the understanding of genomic landscape of pediatric acute myeloid leukemia (pedAML), targeted treatments are only available for selected genomic alterations and the functional link between genotype and outcome remains partially elusive. Functional precision medicine approaches to investigate treatment resistance and patient risk have not been applied systematically for pedAML. We established an advanced functional screening platform combining high-content imaging and deep-learning-based phenotyping. In 45 pedAML patients, we identify BCL2 and FLT3 inhibitors and standard chemotherapy as major drivers of the chemosensitivity landscape, reveal substantial differential sensitivities between risk groups, and may effectively predict individual measurable residual disease and patient risk. Integration with genomic and epigenomic data uncovers a chemotherapy-resistant primitive state vulnerable to combined BCL2 and MDM2 inhibition and HDAC inhibition. Overall, we identify early present signatures of therapy resistance across genetic subgroups and prioritize targeted treatments for these functionally and epigenetically defined patient subsets.
Published in
Haladik B, Maurer-Granofszky M, Zoescher P et al.
· Cell reports. Medicine 2025
· PMID 40840446
· doi:10.1016/j.xcrm.2025.102304
This dataset
Download
Direct links to NCBI, no account and no request form: the whole study as GSE282258_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 44 samples. Raw sequencing reads are also available from ENA.
Also filed as BioProject PRJNA1187806 and SRA study SRP546075. Searching any of these in the dataset finder brings you back here.
Study design
40 conditions, each sampled once — no replicated groups
Read from the first 40 of 44 sample titles: 40 distinct titles with little repetition. Check it against the sample list below before relying on it.
Samples in this study
0 selected
- GSM8640064 AML74_UBTF
- GSM8640065 AML84_complex
- GSM8640066 AML13_KMT2Ar
- GSM8640067 AML39_DEKNUP214
- GSM8640068 AML44_NUP98r
- GSM8640069 AML66_CBFB
- GSM8640070 AML47_CBFB
- GSM8640071 AML58_NK
- GSM8640072 AML63_NUP98
- GSM8640073 AML62_DEKNUP214
- GSM8640074 AML59_CBFB
- GSM8640075 AML20_NK
- GSM8640076 AML77_trisomy8
- GSM8640077 AML26_CBFB
- GSM8640078 AML88_mono7
- GSM8640079 AML95_MECOM1
- GSM8640080 AML54_KMT2Ar
- GSM8640081 AML07_KMT2Ar
- GSM8640082 AML60_CBFB
- GSM8640083 AML98_CBFB
- GSM8640084 AML89_RUNX1
- GSM8640085 AML82_NK
- GSM8640086 AML76_KMT2Ar
- GSM8640087 AML87_NK
- GSM8640088 AML50_GLISr
- GSM8640089 AML52_KMTA2Ar
- GSM8640090 AML65_KMT2Ar
- GSM8640091 AML23_KMT2Ar
- GSM8640092 AML67_KMT2Ar
- GSM8640093 AML28_NK
- GSM8640094 AML64_NK
- GSM8640095 AML24_UBTF
- GSM8640096 AML43_NK
- GSM8640097 AML04_NK
- GSM8640098 AML81_other
- GSM8640099 AML17_NUP98r
- GSM8640100 AML12_NUP98r
- GSM8640101 AML31_BCRABL1
- GSM8640102 AML93_ETV6
- GSM8640103 AML06_NUP98r
+ 4 more — browse all 44 samples with per-sample file links →
Similar datasets
- GSE334112 Reversible epiblast regionalisation determines differentiation potential of human PSCs [ATAC-seq] 38 samples
- GSE316389 Chromatin accessibility and gene expression profiling of primary and metastatic ER+ breast cancer [ATAC-seq] 36 samples
- GSE301512 Chromatin topology dynamics of dexamethasone-treated trabecular meshwork identifies 78 causal genes for intraocular pressure and primary open angle glaucoma [CUT&Run] 30 samples
- GSE288843 Multiomic assessments of LNCaP and derived cell strains reveal determinants of prostate cancer pathobiology (ATAC-Seq) 30 samples
- GSE318521 An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma [ATAC-seq] 24 samples
- GSE278073 Targeting VRK2 Enhances the Efficacy of Anti-PD-1 Therapy in Hepatocellular Carcinoma by Reducing Direct Phosphorylation and Stability of MYC: CUT-TAG sequencing for MYC in hepatocellular carcinoma cells 16 samples
- GSE316079 SLF2 and SMC5 dysfunction drives HSC aging and predisposes to MDS, defining a new inherited bone marrow failure syndrome [ATAC-seq] 6 samples
- GSE142751 Genome-wide maps of chromatin state in 142 cancer cell lines [cell line] 855 samples
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.